-
These Companies Probably Won't Be Acquiring Ariad Pharmaceuticals
Saturday, April 18, 2015 - 10:49am | 338Read More...Adam Feuerstein was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick. TheStreet Senior Columnist Adam Feuerstein responded to an article in the Boston Business Journal which suggested that Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA)...
-
Adam Feuerstein Is A Skeptic Of Stem Cell Therapy
Saturday, April 18, 2015 - 10:46am | 259Read More...Adam Feuerstein was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick. TheStreet Senior Columnist Adam Feuerstein discussed Cytori Therapeutics Inc (NASDAQ: CYTX) on the show. Overall, Feuerstein was skeptical of stem cell therapy...
-
Expert: Bluebird Bio Is 'One Of The Better Stories In Biotech'
Friday, April 17, 2015 - 3:03pm | 259Read More...Adam Feuerstein was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick. TheStreet Senior Columnist Adam Feuerstein discussed bluebird bio Inc (NASDAQ: BLUE) on the show and said that it was “one of the better stories in biotech over...
-
Why Bristol-Myers Squibb Ending A Drug Trial Early Is A Good Thing
Friday, April 17, 2015 - 1:47pm | 221Read More...Adam Feuerstein was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick.. TheStreet Senior Columnist Adam Feuerstein discussed Bristol-Myers Squibb Co (NYSE: BMY) on the show. Feuerstein pointed out that the company announced Friday...
-
Adam Feuerstein Says If You Believe In A Biotech Bubble, It Hasn't Burst
Friday, April 17, 2015 - 1:18pm | 353Read More...Adam Feuerstein was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick. Feuerstein thinks the concept of a biotech bubble is simplistic. "We're still debating whether a biotech bubble exists or not," Feuerstein told...
-
10 Biotech Experts To Follow On Twitter
Wednesday, April 15, 2015 - 1:47pm | 1357Read More...Do you think we're in a biotech bubble? Find out how you can join the experts in a discussion about the most profitable investments in the biotechnology and pharmaceutical sectors here. Let's be honest: biotech is hot right now. But investors might be wondering where to find more...
-
#PreMarket Prep Guest List For The Week Of April 13: Get Ready For The #BestofBiotech
Monday, April 13, 2015 - 8:04am | 1300Read More...Get ready for our #BestofBiotech show featuring biotech traders and experts like TheStreet's Adam Feuerstein on this week's #PreMarket Prep! Be sure to tune in at 8:00 a.m. EST Monday-Friday here interact with our veteran traders, market technicians and money managers that come on...
-
Pharmacyclics Rumor: How Some Wall Street Analysts Are Reacting
Wednesday, February 25, 2015 - 3:47pm | 300Read More...Oncothyreon Inc (USA) (NASDAQ: ONTY) is up on Wednesday afternoon after a rumor of a possible move on Pharmacyclics, Inc. (NASDAQ: PCYC) hit the wires. Pharmacyclics is up nearly 17 percent. Adam Feuerstein (@adamfeuerstein), of TheStreet, tweeted a note on the news from Bernstein's trading...
-
How Adam Feuerstein Follows The Biotech Sector
Friday, November 14, 2014 - 11:11am | 462Read More...Anyone who trades or invests in biotech stocks knows how volatile they can be, according to Adam Feuerstein. Feuerstein is a senior columnist for TheStreet.com, and he recently joined Benzinga’s #PreMarket Prep to talk about how he keeps track of what’s going on in the biotech...
-
Arrowhead Research Corp Down Big On Disappointing Hepatitis B Drug Data
Wednesday, October 8, 2014 - 11:41am | 188Read More...Shares of Arrowhead Research Corp (NASDAQ: ARWR) are down sharply following tweets by Adam Feuerstein pointing to disappointing data on its Hepatitis B drug. In case you're wondering, $ARWR selling off bc ARC-520 HepB data in #AASLD14 abstract just released are disappointing. — Adam...
-
Amarin Moves Higher On Speculation Of Special Protocol Assessment
Thursday, July 31, 2014 - 12:01pm | 290Read More...Amarin (NASDAQ: AMRN) moved higher Thursday following upbeat biotech commentary from TheStreet.com's Adam Feuerstein. Feuerstein mentioned that Amarin, “is expected to hear soon on an appeal to a top official at the FDA requesting a reversal of the Special Protocol Assessment (SPA) covering the...
-
OHR Pharmaceuticals Selling Off As Feuerstein Calls Phase II A Failure
Tuesday, June 24, 2014 - 1:17pm | 176Read More...Shares of OHR Pharmaceuticals (NASDAQ: OHRP) are tumbling after Adam Feuerstein laid out the failure of the company’s phase II study. As Feuerstein explained, the report looks positive; the title even totes “positive” results. This left many investors wondering why shares were...
-
Market Wrap For May 20: Markets Sharply Lower On Fed Talk, Disappointing Earnings
Tuesday, May 20, 2014 - 4:42pm | 2471Read More...U.S. stocks declined following troubling words from a Federal Reserve official. In a speech delivered Tuesday, the Fed's Charles Plosser hinted that the Federal Reserve should reduce the pace of its asset purchases in measured steps but an increase in interest rates “may come sooner than many...
-
Intercept Pharmaceuticals Tumbles On Safety Concern Allegations
Tuesday, May 20, 2014 - 11:02am | 242Read More...Intercept Pharmaceuticals (NASDAQ: ICPT) shares were trading in the red Tuesday morning. The stock traded down to $215, a 17.3 percent drop after Adam Feuerstein of The Street said government scientists are concerned about the safety of the drug. However, the stock began a recovery shortly...
-
Chelsea Notes 'Abnormal Trading Activity' Surrounding Today's PDUFA Action
Friday, February 14, 2014 - 2:49pm | 589Read More...Shares of Chelsea Therapeutics International (NASDAQ: CHTP) have been volatile throughout Friday, halting three times on a circuit breaker before 11:35 a.m. EST. Investors are positioning themselves ahead of a very important PDUFA date for Northera (droxidopa), expected out sometime Friday...
